Related Experiment Video

Updated: Apr 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

[Possible Choice of New Oral Anticoagulants With Non-Valvular Atrial Fibrillation: a Review of Meta-Analyzes]

B A Tatarskiĭ, N V Kazennova

    Kardiologiia
    |September 1, 2015
    PubMed

    Insights

    New oral anticoagulants significantly reduce stroke, intracranial hemorrhage, and mortality in non-valvular atrial fibrillation patients. While increasing gastrointestinal bleeding, these anticoagulants offer a favorable risk-benefit profile for stroke prevention.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Evidence-based Medicine

    Context:

    • Non-valvular atrial fibrillation (NVAF) poses a significant risk for stroke and systemic embolism.
    • Traditional anticoagulants have limitations, necessitating safer and more effective alternatives.
    • Newer oral anticoagulants (NOACs) have emerged as a promising therapeutic option.

    Purpose:

    • To conduct a meta-analysis of all available studies on new oral anticoagulants (NOACs).
    • To evaluate the efficacy and safety of NOACs in preventing stroke or systemic embolism in NVAF patients.
    • To compare the risk-benefit profile of NOACs against established treatments.

    Summary:

    • Meta-analysis of four studies involving NOACs for stroke prevention in NVAF patients.
    • NOACs demonstrated significant reductions in stroke, intracranial hemorrhage, and mortality.
    • A noted increase in gastrointestinal bleeding was observed with NOACs.
    • Consistent efficacy and safety profiles were observed across diverse patient subgroups.
    • NOACs present a favorable risk-benefit profile for NVAF management.

    Impact:

    • Provides comprehensive data on the efficacy and safety of NOACs in a large patient cohort.
    • Supports the use of NOACs as a valuable therapeutic strategy for stroke risk reduction in NVAF.
    • Informs clinical decision-making regarding anticoagulant selection for NVAF patients.
    • Highlights the need for monitoring gastrointestinal bleeding risk when prescribing NOACs.

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    34.4K
    Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

    Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

    Published on: February 8, 2022

    4.5K

    Related Concept Videos

    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    2.4K
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    2.8K
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    466
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    1.5K
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    4.1K
    Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

    Cardiovascular Drugs: Classification based on Therapeutic Indications

    Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
    4.6K